WHO

Noncommunicable diseases in the 2011 global public health agenda

Noncommunicable diseases (NCDs) enjoy a place of prominence on the global public health agenda in 2011. At the 128th WHO EB, the assembly was abuzz with news of a joint Russian and WHO initiative, the "First global ministerial conference on healthy lifestyles and noncommunicable disease control" to be held in Moscow on 28-29 April 2011 and the UN High-level Meeting of the General Assembly on Non-Communicable Diseases in September 2011.

Le Monde: L’OMS face à un nouveau conflit d’intérêts

The following is an article by Agathe Duparc which appeared on page four of the Sunday/Monday edition (23 January-24 January 2011) of Le Monde with a reference on the cover page. Below the article are two paragraphs providing readers with more background information on the World Health Assembly and the Executive Board. The third paragraph is the main quote highlighted in the print version. What is missing in this copy below is a cartoon accompanying the piece which shows a bespectacled man with a body of an octopus holding two syringes in a field of dollar signs.

Response to Mary Moran on managing conflicts of interest at the WHO CEWG

This is a response to an email message posted to a2k and ip-health by Dr. Mary Moran. Among other things, the missive raises the issue of what constitutes a conflict of interest, and also how such conflicts should be managed. Dr. Moran has asked for a response, and this is it.

Dear Dr. Moran,

WHO Executive Board accepts appointment of Herrling to Consultative Expert Working Group on R&D

After several days of negotiations, the 128th WHO Executive Board has accepted the nomination of Paul Herrling to the new WHO Consultative Expert Working Group on R&D Financing, despite the fact that Herrling is an executive of Novartis, and is the author of the IFPMA/Novartis/FRIND proposal and the co-author of the PDP Plus proposal, which will be considered by the CEWG.

Nine civil society groups write WHO Executive Board about conflict of interest on WHO R&D Financing group

On January 20, 2011, 9 civil society organizations sent a letter to the WHO Executive Board registering an objection to the selection of Dr. Paul Herrling of Novartis to the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination. The groups signing the letter were:

  • CIDEPRO
  • Déclaration de Berne - Berne Declaration
  • HAI Europe
  • HAI Global
  • Health GAP (Global Access Project)

WHO Conflict of Interest Guidelines

WHO has kindly made available its conflict of interest guidelines. Apparently they are not available from the public web page. Attached are two documents:

A few of the many interesting provisions follow:

I. MEANING OF "CONFLICT OF INTEREST"

European members of WHO Executive Board take hard line on nomination of Novartis official to R&D group

At the 128th meeting of the WHO Executive Board (EB), the European members of the board are reportedly taking a hard line on the proposal by Switzerland to have Paul Herrling, an executive of Novartis, appointed to the WHO Consultative Expert Working Group (CEWG) on R&D financing. Our earlier blogs on this controversy are available here and here).

Conflicts of Interest, and the WHO evaluation of the FRIND and the PDP Plus funding proposals by the CEWG

This note provide additional context for those who are just now following the issue of conflicts of interest and the WHO Consultative Expert Working Group (CEWG) on R&D Financing.

The CEWG follows a controversial, flawed and failed effort by an earlier group, the WHO Expert Working Group (EWG) on R&D Financing, to:

CEWG: WHO Consultative Expert Group on R&D Financing

The WHO EB debate over membership of the new R&D Financing consultative expert working group (CEWG)

At the end of the day on Monday, the 128 WHO Executive Board meeting took the agenda item for creation of a new R&D Financing consultative expert working group (CEWG). (Yesterday's blog on this topic is here)

Syndicate content